Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, day 14 68% Improvement Relative Risk Mortality, day 7 3% ICU admission 35% Hospitalization time 25% Viral clearance 18% Favipiravir  Hassaniazad et al.  LATE TREATMENT  RCT Is late treatment with favipiravir beneficial for COVID-19? RCT 63 patients in Iran Trial compares with lopinavir/ritonavir, results vs. placebo may differ Lower mortality (p=0.15) and ICU admission (p=0.51), not sig. c19early.org Hassaniazad et al., J. Medical Virology, Mar 2022 Favors favipiravir Favors lopinavir/ri..

Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial

Hassaniazad et al., Journal of Medical Virology, doi:10.1002/jmv.27724, IRCT20200506047323N3
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT comparing favipiravir and lopinavir/ritonavir, showing no significant differences. All patients received interferon-beta. Favipiravir 1600mg bid for the first day and 600mg bid for the following 4 days.
risk of death, 67.7% lower, RR 0.32, p = 0.15, treatment 2 of 32 (6.2%), control 6 of 31 (19.4%), NNT 7.6, day 14.
risk of death, 3.1% lower, RR 0.97, p = 1.00, treatment 1 of 32 (3.1%), control 1 of 31 (3.2%), NNT 992, day 7.
risk of ICU admission, 35.4% lower, RR 0.65, p = 0.51, treatment 4 of 32 (12.5%), control 6 of 31 (19.4%), NNT 15, day 14.
hospitalization time, 25.0% lower, relative time 0.75, p = 0.14, treatment 32, control 31.
risk of no viral clearance, 18.0% lower, RR 0.82, p = 0.24, treatment 22 of 32 (68.8%), control 26 of 31 (83.9%), NNT 6.6, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hassaniazad et al., 24 Mar 2022, Randomized Controlled Trial, Iran, peer-reviewed, mean age 53.8, 7 authors, this trial compares with another treatment - results may be better when compared to placebo, trial IRCT20200506047323N3. Contact: m.fathalipour@yahoo.com.
This PaperFavipiravirAll
Efficacy and safety of favipiravir plus interferon‐beta versus lopinavir/ritonavir plus interferon‐beta in moderately ill patients with COVID‐19: A randomized clinical trial
Mehdi Hassaniazad, Hossein Farshidi, Abdollah Gharibzadeh, Ali Bazram, Elham Khalili, Afsaneh Noormandi, Mohammad Fathalipour
Journal of Medical Virology, doi:10.1002/jmv.27724
Favipiravir (FVP), lopinavir/ritonavir (LPV/RTV), and interferon-beta (INF-beta) are considered as potential treatments for COVID-19. We examined the efficacy and safety of FVP and INF-beta compared to LPV/RTV and INF-beta combinations for the treatment of SARS-CoV-2. It was a single-center randomized clinical trial. Eligible patients were randomized to receive FVP plus INF-beta versus LPV/RTV plus INF-beta. The primary endpoint was the viral clearance after seven days of randomization. ICU admission, length of stay (LOS) in hospital, in-hospital mortality, and the incidence of adverse events were also measured. This trial was registered on the Iranian Registry of Clinical Trials (IRCT20200506047323N3). Patients were randomly allocated to the FVP (n = 33) and LPV/RTV (n = 33) groups. The viral clearance on Day seven was not significantly different between the FVP (31.1%) and the LPV/RTV groups (16.1%). The rate of ICU admission and likewise the in-hospital mortality in the FVP group (12.5% and 6.3%, respectively) were similar to the LPV/RTV groups (19.4% and 19.4%, respectively). The median LOS in the hospital was also not different (6.8 days [interquartile range; IQR = 5.0-11.0] in the FVP and (8.0 days [IQR = 5.5-12.5]) in LPV/RTV groups (p = 0.140). Adverse events were observed in 25.0% of FVP and 32.3% of LPV/RTV groups. The combination therapy with FVP did not exert a higher efficacy compared to the combination regimen of LPV/RTV. However, both treatment regimens demonstrated a mild profile of adverse events.
ACKNOWLEDGMENTS The authors appreciably thank the trial patients and their families, whose help and participation made this study possible. This study was financially supported by Hormozgan University of Medical Sciences (Grant no: 990233). CONFLICTS OF INTEREST The authors declare no conflicts of interest. SUPPORTING INFORMATION Additional supporting information may be found in the online version of the article at the publisher's website.
References
Alhumaid, Mutair, Alawi, Alhmeed, Zaidi et al., Efficacy and safety of lopinavir/ritonavir for treatment of covid-19: a systematic review and meta-analysis, Trop Med Infect Dis
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering
Chen, Zhang, Huang, Favipiravir versus Arbidol for COVID-19: a Randomized Clinical Trial, medRxiv, doi:10.1101/2020.03.17.20037432
Dabbous, El-Sayed, Assal, A randomized controlled study of favipiravir vs hydroxychloroquine in COVID-19 management: what have we learned so far?, Res Sq
Davoudi-Monfared, Rahmani, Khalili, A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19, Antimicrob Agents Chemother
Doi, Hibino, Hase, A prospective, randomized, openlabel trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother
Erdem, Ekren, Çağlayan, Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey, Turk J Med Sci
Garnier, Vaucher, Bianchi, Organizational impacts and clinical challenges of the COVID-19 pandemic on a Swiss Tertiary Internal Medicine Department, Rev Med Suisse
Hassaniazad, Bazram, Hassanipour, Fathalipour, Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial, Trials
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep
Joseph, Dibas, Evanson, Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: a systematic review, Expert Rev Anti Infect Ther
Khamis, Naabi, Lawati, Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia, Int J Infect Dis
Lou, Liu, Yao, Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial, Eur J Pharm Sci
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Erad
Romera-Liebana, Orfila, Segura, Effects of a primary care-based multifactorial intervention on physical and cognitive function in frail, elderly individuals: a randomized controlled trial, J Gerontol A Biol Sci Med Sci
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol J
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis
Zhao, Zhu, Zhang, Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size, Biomed Pharmacother
{ 'DOI': '10.1002/jmv.27724', 'ISSN': ['0146-6615', '1096-9071'], 'URL': 'http://dx.doi.org/10.1002/jmv.27724', 'alternative-id': ['10.1002/jmv.27724'], 'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2021-11-01'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 1, 'value': '2022-03-14'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 2, 'value': '2022-03-24'}], 'author': [ { 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Hormozgan ' 'Health Institute Hormozgan University of Medical Sciences ' 'Bandar Abbas Iran'}], 'family': 'Hassaniazad', 'given': 'Mehdi', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Cardiovascular Research Center Hormozgan University of Medical ' 'Sciences Bandar Abbas Iran'}], 'family': 'Farshidi', 'given': 'Hossein', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Social Determinants in Health Promotion Research Center, ' 'Hormozgan Health Institute Hormozgan University of Medical ' 'Sciences Bandar Abbas Iran'}], 'family': 'Gharibzadeh', 'given': 'Abdollah', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Hormozgan ' 'Health Institute Hormozgan University of Medical Sciences ' 'Bandar Abbas Iran'}], 'family': 'Bazram', 'given': 'Ali', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-8354-9426', 'affiliation': [ { 'name': 'Student Research Committee Hormozgan University of Medical ' 'Sciences Bandar Abbas Iran'}], 'authenticated-orcid': False, 'family': 'Khalili', 'given': 'Elham', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Inpatient Services Iran Food and Drug ' 'Administration Tehran Iran'}], 'family': 'Noormandi', 'given': 'Afsaneh', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-4568-7024', 'affiliation': [ { 'name': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy ' 'Hormozgan University of Medical Sciences Bandar Abbas Iran'}, { 'name': 'Endocrinology and Metabolic Research Center Hormozgan University ' 'of Medical Sciences Bandar Abbas Iran'}], 'authenticated-orcid': False, 'family': 'Fathalipour', 'given': 'Mohammad', 'sequence': 'additional'}], 'container-title': 'Journal of Medical Virology', 'container-title-short': 'Journal of Medical Virology', 'content-domain': {'crossmark-restriction': True, 'domain': ['onlinelibrary.wiley.com']}, 'created': {'date-parts': [[2022, 3, 16]], 'date-time': '2022-03-16T08:26:15Z', 'timestamp': 1647419175000}, 'deposited': { 'date-parts': [[2022, 3, 24]], 'date-time': '2022-03-24T21:29:29Z', 'timestamp': 1648157369000}, 'funder': [ { 'DOI': '10.13039/501100011917', 'doi-asserted-by': 'publisher', 'name': 'Hormozgan University of Medical Sciences'}], 'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T21:06:05Z', 'timestamp': 1648933565306}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 3, 24]]}, 'language': 'en', 'license': [ { 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 3, 24]], 'date-time': '2022-03-24T00:00:00Z', 'timestamp': 1648080000000}}, { 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 3, 24]], 'date-time': '2022-03-24T00:00:00Z', 'timestamp': 1648080000000}}], 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27724', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.27724', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27724', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '311', 'original-title': [], 'prefix': '10.1002', 'published': {'date-parts': [[2022, 3, 24]]}, 'published-online': {'date-parts': [[2022, 3, 24]]}, 'publisher': 'Wiley', 'reference': [ {'DOI': '10.1016/j.eng.2020.03.007', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_2_1'}, { 'article-title': 'A prospective, randomized, open‐label trial of early versus late ' 'favipiravir therapy in hospitalized patients with COVID‐19', 'author': 'Doi Y', 'first-page': '12', 'journal-title': 'Antimicrob Agents Chemother', 'key': 'e_1_2_10_3_1', 'volume': '64', 'year': '2020'}, { 'article-title': 'Favipiravir versus Arbidol for COVID‐19: a Randomized Clinical Trial', 'author': 'Chen C', 'journal-title': 'medRxiv', 'key': 'e_1_2_10_4_1', 'year': '2020'}, { 'DOI': '10.1016/j.biopha.2020.110825', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_5_1'}, { 'DOI': '10.1093/gerona/glx259', 'article-title': 'Effects of a primary care‐based multifactorial intervention on physical ' 'and cognitive function in frail, elderly individuals: a randomized ' 'controlled trial', 'author': 'Romera‐Liebana L', 'doi-asserted-by': 'crossref', 'first-page': '1688', 'issue': '12', 'journal-title': 'J Gerontol A Biol Sci Med Sci', 'key': 'e_1_2_10_6_1', 'volume': '73', 'year': '2018'}, { 'DOI': '10.1080/14787210.2021.1848545', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_7_1'}, { 'article-title': 'Efficacy and safety of lopinavir/ritonavir for treatment of covid‐19: a ' 'systematic review and meta‐analysis', 'author': 'Alhumaid S', 'first-page': '4', 'journal-title': 'Trop Med Infect Dis', 'key': 'e_1_2_10_8_1', 'volume': '5', 'year': '2020'}, {'DOI': '10.1016/j.ijid.2020.11.008', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_9_1'}, { 'DOI': '10.1128/AAC.01061-20', 'article-title': 'A randomized clinical trial of the efficacy and safety of interferon ' 'β‐1a in treatment of severe COVID‐19', 'author': 'Davoudi‐Monfared E', 'doi-asserted-by': 'crossref', 'first-page': '9', 'journal-title': 'Antimicrob Agents Chemother', 'key': 'e_1_2_10_10_1', 'volume': '64', 'year': '2020'}, { 'DOI': '10.1016/j.ejps.2020.105631', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_11_1'}, { 'DOI': '10.1186/s13063-020-04747-8', 'article-title': 'Evaluation of the efficacy and safety of favipiravir and interferon ' 'compared to lopinavir/ritonavir and interferon in moderately ill ' 'patients with COVID‐19: a structured summary of a study protocol for a ' 'randomized controlled trial', 'author': 'Hassaniazad M', 'doi-asserted-by': 'crossref', 'first-page': '886', 'issue': '1', 'journal-title': 'Trials', 'key': 'e_1_2_10_12_1', 'volume': '21', 'year': '2020'}, { 'DOI': '10.3906/sag-2008-33', 'article-title': 'Treatment of SARS‐CoV‐2 pneumonia with favipiravir: early results from ' 'the Ege University cohort, Turkey', 'author': 'Erdem HA', 'doi-asserted-by': 'crossref', 'first-page': '912', 'issue': '3', 'journal-title': 'Turk J Med Sci', 'key': 'e_1_2_10_13_1', 'volume': '51', 'year': '2021'}, { 'DOI': '10.1186/s12985-020-01412-z', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_14_1'}, { 'article-title': 'Organizational impacts and clinical challenges of the COVID‐19 pandemic ' 'on a Swiss Tertiary Internal Medicine Department', 'author': 'Garnier A', 'first-page': '869', 'issue': '691', 'journal-title': 'Rev Med Suisse', 'key': 'e_1_2_10_15_1', 'volume': '16', 'year': '2020'}, { 'DOI': '10.1038/s41598-021-90551-6', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_16_1'}, { 'DOI': '10.1016/j.ijid.2020.11.142', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_17_1'}, { 'article-title': 'A randomized controlled study of favipiravir vs hydroxychloroquine in ' 'COVID‐19 management: what have we learned so far?', 'author': 'Dabbous HM', 'journal-title': 'Res Sq', 'key': 'e_1_2_10_18_1', 'year': '2020'}, { 'DOI': '10.1016/S2055-6640(20)30016-9', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_10_19_1'}], 'reference-count': 18, 'references-count': 18, 'relation': {}, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/jmv.27724'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Virology'], 'subtitle': [], 'title': 'Efficacy and safety of favipiravir plus interferon‐beta versus lopinavir/ritonavir plus ' 'interferon‐beta in moderately ill patients with COVID‐19: A randomized clinical trial', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit